Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary

• Published in: International journal of clinical oncology Vol. 21; no. 1; pp. 1 - 12
• Main Authors: Takeuchi, Hideki, Saeki, Toshiaki, Aiba, Keisuke, Tamura, Kazuo, Aogi, Kenjiro, Eguchi, Kenji, Okita, Kenji, Kagami, Yoshikazu, Tanaka, Ryuhei, Nakagawa, Kazuhiko, Fujii, Hirofumi, Boku, Narikazu, Wada, Makoto, Akechi, Tatsuo, Udagawa, Yasuhiro, Okawa, Yutaka, Onozawa, Yusuke, Sasaki, Hidenori, Shima, Yasuo, Shimoyama, Naohito, Takeda, Masayuki, Nishidate, Toshihiko, Yamamoto, Akifumi, Ikeda, Tadashi, Hirata, Koichi
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.02.2016; Springer Nature B.V
• Subjects: Antiemetics - therapeutic use; Antineoplastic Agents - adverse effects; Cancer; Cancer Research; Chemotherapy; Dexamethasone - therapeutic use; Drug therapy; Humans; Japan; Medical Oncology; Medicine; Medicine & Public Health; Nausea; Nausea - chemically induced; Nausea - drug therapy; Oncology; Practice Guidelines as Topic; Serotonin 5-HT3 Receptor Antagonists - therapeutic use; Side effects; Societies, Medical; Special; Special Article; Surgical Oncology; Time Factors; Vomiting; Vomiting - chemically induced; Vomiting - drug therapy; Japan; Clinical practice guideline; Antiemetic treatment; Cancer chemotherapy
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-015-0852-1

The purpose of this article is to disseminate the standard of antiemetic therapy for Japanese clinical oncologists. On the basis of the Appraisal of Guidelines for Research and Evaluation II instrument, which reflects evidence-based clinical practice guidelines, a working group of the Japanese Society of Clinical Oncology (JSCO) reviewed clinical practice guidelines for antiemesis and performed a systematic review of evidence-based domestic practice guidelines for antiemetic therapy in Japan. In addition, because health-insurance systems in Japan are different from those in other countries, a consensus was reached regarding standard treatments for chemotherapy that induce nausea and vomiting. Current evidence was collected by use of MEDLINE, from materials from meetings of the American Society of Clinical Oncology National Comprehensive Cancer Network, and from European Society of Medical Oncology/Multinational Association of Supportive Care in Cancer guidelines for antiemesis. Initially, 21 clinical questions (CQ) were selected on the basis of CQs from other guidelines. Patients treated with highly emetic agents should receive a serotonin (5-hydroxytryptamine; 5HT 3 ) receptor antagonist, dexamethasone, and a neurokinin 1 receptor antagonist. For patients with moderate emetic risk, 5HT 3 receptor antagonists and dexamethasone were recommended, whereas for those receiving chemotherapy with low emetic risk dexamethasone only is recommended. Patients receiving high-emetic-risk radiation therapy should also receive a 5HT 3 receptor antagonist. In this paper the 2010 JSCO clinical practice guidelines for antiemesis are presented in English; they reveal high concordance of Japanese medical circumstances with other antiemetic guidelines that are similarly based on evidence.